BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig; Alejandro Forner; Jordi Rimola; Joana Ferrer-Fàbrega; Marta Burrel; Ángeles Garcia-Criado; Robin K. Kelley; Peter R. Galle; Vincenzo Mazzaferro; Riad Salem; Bruno Sangro; Amit G. Singal; Arndt Vogel; Josep Fuster; Carmen Ayuso; Jordi Bruix

doi:10.1016/j.jhep.2021.11.018

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig^*, Alejandro Forner, Jordi Rimola, Joana Ferrer-Fàbrega, Marta Burrel, Ángeles Garcia-Criado, Robin K. Kelley, Peter R. Galle, Vincenzo Mazzaferro, Riad Salem, Bruno Sangro, Amit G. Singal, Arndt Vogel, Josep Fuster, Carmen Ayuso, Jordi Bruix

^*Corresponding author for this work

Radiology

Research output: Contribution to journal › Review article › peer-review

1804 Scopus citations

Abstract

There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

Original language	English (US)
Pages (from-to)	681-693
Number of pages	13
Journal	Journal of Hepatology
Volume	76
Issue number	3
DOIs	https://doi.org/10.1016/j.jhep.2021.11.018
State	Published - Mar 2022

Funding

MR: Dr. Reig’s research is partially supported by Instituto de Salud Carlos III ( PI15/00145 and PI18/0358 ) and from the Spanish Health Ministry (National Strategic Plan against Hepatitis C). AF: Dr. Forner’s research is partially supported by Instituto de Salud Carlos III ( PI13/01229 and PI18/00542 ). JR: Dr. Rimola’s research is partially supported by grant from European Association for the Study of the Liver (EASL) . BS: Dr. Sangro’s research is partially supported by ISCIII/EU TRANSCAN-2 ( AC16/00065 ), and Instituto de Salud Carlos III ( PI19/00742 ). AS: Dr. Singal’s research is supported by National Institute of Health R01 R01 MD012565 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. JB: Dr. Bruix’s research is partially supported by Instituto de Salud Carlos III ( PI18/00768 ), the Spanish Health Ministry (National Strategic Plan against Hepatitis C) and AECC ( PI044031 ). CIBERehd: is funded by the Instituto de Salud Carlos III . Dr. Rimola, Dr. Reig and Dr. Bruix are partially funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 952103. MR: Dr. Reig's research is partially supported by Instituto de Salud Carlos III (PI15/00145 and PI18/0358) and from the Spanish Health Ministry (National Strategic Plan against Hepatitis C). AF: Dr. Forner's research is partially supported by Instituto de Salud Carlos III (PI13/01229 and PI18/00542). JR: Dr. Rimola's research is partially supported by grant from European Association for the Study of the Liver (EASL). BS: Dr. Sangro's research is partially supported by ISCIII/EU TRANSCAN-2 (AC16/00065), and Instituto de Salud Carlos III (PI19/00742). AS: Dr. Singal's research is supported by National Institute of Health R01 R01 MD012565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. JB: Dr. Bruix's research is partially supported by Instituto de Salud Carlos III (PI18/00768), the Spanish Health Ministry (National Strategic Plan against Hepatitis C) and AECC (PI044031). CIBERehd: is funded by the Instituto de Salud Carlos III. Dr. Rimola, Dr. Reig and Dr. Bruix are partially funded from the European Union's Horizon 2020 research and innovation programme under grant agreement No 952103.

Keywords

AFP
ALBI score
BCLC
HCC
TARE
ablation
liver transplantation TACE
surgery
survival
systemic treatment

ASJC Scopus subject areas

Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jhep.2021.11.018

Cite this

Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 76(3), 681-693. https://doi.org/10.1016/j.jhep.2021.11.018

@article{7da620cd45f247749ee851e21678c65e,

title = "BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update",

abstract = "There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.",

keywords = "AFP, ALBI score, BCLC, HCC, TARE, ablation, liver transplantation TACE, surgery, survival, systemic treatment",

author = "Maria Reig and Alejandro Forner and Jordi Rimola and Joana Ferrer-F{\`a}brega and Marta Burrel and {\'A}ngeles Garcia-Criado and Kelley, {Robin K.} and Galle, {Peter R.} and Vincenzo Mazzaferro and Riad Salem and Bruno Sangro and Singal, {Amit G.} and Arndt Vogel and Josep Fuster and Carmen Ayuso and Jordi Bruix",

note = "Publisher Copyright: {\textcopyright} 2021 European Association for the Study of the Liver",

year = "2022",

month = mar,

doi = "10.1016/j.jhep.2021.11.018",

language = "English (US)",

volume = "76",

pages = "681--693",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "3",

}

Reig, M, Forner, A, Rimola, J, Ferrer-Fàbrega, J, Burrel, M, Garcia-Criado, Á, Kelley, RK, Galle, PR, Mazzaferro, V, Salem, R, Sangro, B, Singal, AG, Vogel, A, Fuster, J, Ayuso, C & Bruix, J 2022, 'BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update', Journal of Hepatology, vol. 76, no. 3, pp. 681-693. https://doi.org/10.1016/j.jhep.2021.11.018

TY - JOUR

T1 - BCLC strategy for prognosis prediction and treatment recommendation

T2 - The 2022 update

AU - Reig, Maria

AU - Forner, Alejandro

AU - Rimola, Jordi

AU - Ferrer-Fàbrega, Joana

AU - Burrel, Marta

AU - Garcia-Criado, Ángeles

AU - Kelley, Robin K.

AU - Galle, Peter R.

AU - Mazzaferro, Vincenzo

AU - Salem, Riad

AU - Sangro, Bruno

AU - Singal, Amit G.

AU - Vogel, Arndt

AU - Fuster, Josep

AU - Ayuso, Carmen

AU - Bruix, Jordi

PY - 2022/3

Y1 - 2022/3

N2 - There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

AB - There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

KW - AFP

KW - ALBI score

KW - BCLC

KW - HCC

KW - TARE

KW - ablation

KW - liver transplantation TACE

KW - surgery

KW - survival

KW - systemic treatment

UR - http://www.scopus.com/inward/record.url?scp=85123587056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123587056&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2021.11.018

DO - 10.1016/j.jhep.2021.11.018

M3 - Review article

C2 - 34801630

AN - SCOPUS:85123587056

SN - 0168-8278

VL - 76

SP - 681

EP - 693

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 3

ER -

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this